Application of a low molecular weight antifungal protein from Penicillium chrysogenum (PAF) to treat pulmonary aspergillosis in mice

Zoltán Palicz, Tamás Gáll, E. Leiter, Sándor Kollár, I. Kovács, Kornél Miszti-Blasius, I. Pócsi, L. Csernoch, P. Szentesi

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

PAF, a small antifungal protein from Penicillium chrysogenum, inhibits the growth of several pathogenic filamentous fungi, including members of the Aspergillus genus. PAF has been proven to have no toxic effects in vivo in mice by intranasal application. To test its efficacy against invasive pulmonary aspergillosis (IPA), experiments were carried out in mice suffering from IPA. Adult mice were immunosuppressed and then infected with Aspergillus fumigatus. After stable infection, the animals were inoculated with PAF intranasally at a concentration of 2.7 mg/kg twice per day. At this concentration - which is highly toxic in vitro to A. fumigatus - the mortality of the animals was slightly delayed but finally all animals died. Histological examinations revealed massive fungal infections in the lungs of both PAF-treated and untreated animal groups. Because intranasally administered PAF was unable to overcome IPA, modified and combined therapies were introduced. The intraperitoneal application of PAF in animals with IPA prolonged the survival of the animals only 1 day. Similar results were obtained with amphotericin B (AMB), with PAF and AMB being equally effective. Combined therapy with AMB and PAF - which are synergistic in vitro - was found to be more effective than either AMB or PAF treatment alone. As no toxic effects of PAF in mammals have been described thus far, and, moreover, there are so far no A. fumigatus strains with reported inherent or acquired PAF resistance, it is worth carrying out further studies to introduce PAF as a potential antifungal drug in human therapy.

Original languageEnglish
Article numbere114
JournalEmerging Microbes and Infections
Volume5
Issue number11
DOIs
Publication statusPublished - Nov 9 2016

Fingerprint

Pulmonary Aspergillosis
Invasive Pulmonary Aspergillosis
Molecular Weight
Amphotericin B
Aspergillus fumigatus
Poisons
Penicillium chrysogenum
Mycoses
Aspergillus
Penicillium chrysogenum PAF protein
Mammals
Fungi
Therapeutics
Lung
Mortality
Growth
Infection
Pharmaceutical Preparations

Keywords

  • antifungal protein
  • histology
  • mouse
  • pulmonary aspergillosis

ASJC Scopus subject areas

  • Parasitology
  • Epidemiology
  • Microbiology
  • Immunology
  • Drug Discovery
  • Infectious Diseases
  • Virology

Cite this

Application of a low molecular weight antifungal protein from Penicillium chrysogenum (PAF) to treat pulmonary aspergillosis in mice. / Palicz, Zoltán; Gáll, Tamás; Leiter, E.; Kollár, Sándor; Kovács, I.; Miszti-Blasius, Kornél; Pócsi, I.; Csernoch, L.; Szentesi, P.

In: Emerging Microbes and Infections, Vol. 5, No. 11, e114, 09.11.2016.

Research output: Contribution to journalArticle

@article{57ade1c03fca481a99aeaec113a197b0,
title = "Application of a low molecular weight antifungal protein from Penicillium chrysogenum (PAF) to treat pulmonary aspergillosis in mice",
abstract = "PAF, a small antifungal protein from Penicillium chrysogenum, inhibits the growth of several pathogenic filamentous fungi, including members of the Aspergillus genus. PAF has been proven to have no toxic effects in vivo in mice by intranasal application. To test its efficacy against invasive pulmonary aspergillosis (IPA), experiments were carried out in mice suffering from IPA. Adult mice were immunosuppressed and then infected with Aspergillus fumigatus. After stable infection, the animals were inoculated with PAF intranasally at a concentration of 2.7 mg/kg twice per day. At this concentration - which is highly toxic in vitro to A. fumigatus - the mortality of the animals was slightly delayed but finally all animals died. Histological examinations revealed massive fungal infections in the lungs of both PAF-treated and untreated animal groups. Because intranasally administered PAF was unable to overcome IPA, modified and combined therapies were introduced. The intraperitoneal application of PAF in animals with IPA prolonged the survival of the animals only 1 day. Similar results were obtained with amphotericin B (AMB), with PAF and AMB being equally effective. Combined therapy with AMB and PAF - which are synergistic in vitro - was found to be more effective than either AMB or PAF treatment alone. As no toxic effects of PAF in mammals have been described thus far, and, moreover, there are so far no A. fumigatus strains with reported inherent or acquired PAF resistance, it is worth carrying out further studies to introduce PAF as a potential antifungal drug in human therapy.",
keywords = "antifungal protein, histology, mouse, pulmonary aspergillosis",
author = "Zolt{\'a}n Palicz and Tam{\'a}s G{\'a}ll and E. Leiter and S{\'a}ndor Koll{\'a}r and I. Kov{\'a}cs and Korn{\'e}l Miszti-Blasius and I. P{\'o}csi and L. Csernoch and P. Szentesi",
year = "2016",
month = "11",
day = "9",
doi = "10.1038/emi.2016.116",
language = "English",
volume = "5",
journal = "Emerging Microbes and Infections",
issn = "2222-1751",
publisher = "Nature Publishing Group",
number = "11",

}

TY - JOUR

T1 - Application of a low molecular weight antifungal protein from Penicillium chrysogenum (PAF) to treat pulmonary aspergillosis in mice

AU - Palicz, Zoltán

AU - Gáll, Tamás

AU - Leiter, E.

AU - Kollár, Sándor

AU - Kovács, I.

AU - Miszti-Blasius, Kornél

AU - Pócsi, I.

AU - Csernoch, L.

AU - Szentesi, P.

PY - 2016/11/9

Y1 - 2016/11/9

N2 - PAF, a small antifungal protein from Penicillium chrysogenum, inhibits the growth of several pathogenic filamentous fungi, including members of the Aspergillus genus. PAF has been proven to have no toxic effects in vivo in mice by intranasal application. To test its efficacy against invasive pulmonary aspergillosis (IPA), experiments were carried out in mice suffering from IPA. Adult mice were immunosuppressed and then infected with Aspergillus fumigatus. After stable infection, the animals were inoculated with PAF intranasally at a concentration of 2.7 mg/kg twice per day. At this concentration - which is highly toxic in vitro to A. fumigatus - the mortality of the animals was slightly delayed but finally all animals died. Histological examinations revealed massive fungal infections in the lungs of both PAF-treated and untreated animal groups. Because intranasally administered PAF was unable to overcome IPA, modified and combined therapies were introduced. The intraperitoneal application of PAF in animals with IPA prolonged the survival of the animals only 1 day. Similar results were obtained with amphotericin B (AMB), with PAF and AMB being equally effective. Combined therapy with AMB and PAF - which are synergistic in vitro - was found to be more effective than either AMB or PAF treatment alone. As no toxic effects of PAF in mammals have been described thus far, and, moreover, there are so far no A. fumigatus strains with reported inherent or acquired PAF resistance, it is worth carrying out further studies to introduce PAF as a potential antifungal drug in human therapy.

AB - PAF, a small antifungal protein from Penicillium chrysogenum, inhibits the growth of several pathogenic filamentous fungi, including members of the Aspergillus genus. PAF has been proven to have no toxic effects in vivo in mice by intranasal application. To test its efficacy against invasive pulmonary aspergillosis (IPA), experiments were carried out in mice suffering from IPA. Adult mice were immunosuppressed and then infected with Aspergillus fumigatus. After stable infection, the animals were inoculated with PAF intranasally at a concentration of 2.7 mg/kg twice per day. At this concentration - which is highly toxic in vitro to A. fumigatus - the mortality of the animals was slightly delayed but finally all animals died. Histological examinations revealed massive fungal infections in the lungs of both PAF-treated and untreated animal groups. Because intranasally administered PAF was unable to overcome IPA, modified and combined therapies were introduced. The intraperitoneal application of PAF in animals with IPA prolonged the survival of the animals only 1 day. Similar results were obtained with amphotericin B (AMB), with PAF and AMB being equally effective. Combined therapy with AMB and PAF - which are synergistic in vitro - was found to be more effective than either AMB or PAF treatment alone. As no toxic effects of PAF in mammals have been described thus far, and, moreover, there are so far no A. fumigatus strains with reported inherent or acquired PAF resistance, it is worth carrying out further studies to introduce PAF as a potential antifungal drug in human therapy.

KW - antifungal protein

KW - histology

KW - mouse

KW - pulmonary aspergillosis

UR - http://www.scopus.com/inward/record.url?scp=84994518950&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994518950&partnerID=8YFLogxK

U2 - 10.1038/emi.2016.116

DO - 10.1038/emi.2016.116

M3 - Article

VL - 5

JO - Emerging Microbes and Infections

JF - Emerging Microbes and Infections

SN - 2222-1751

IS - 11

M1 - e114

ER -